CLINICAL_TRIALS
trial_result
· 2022-12-29
Clinical Trial Update: Ganaxolone in Posttraumatic Stress Disorder (PTSD) [Phase 2]
Summary
Phase 2 clinical trial of ganaxolone in posttraumatic stress disorder has completed with results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Marinus Pharmaceuticals | Conditions: PTSD | Phase 2 | Status: COMPLETED | Results posted: 2022-12-29